The brain is extremely complicated three dimensional structures made up of interconnected neurons and neuroglia cells. It entails all type of functions of our body whether we are healthy or in disease conditions. Brain is accountable for our connectivity with the surroundings; all this is performed by an organized and systemic electrical activity of neurons by which they communicate messages to and from the brain. The abnormal electrical activity leading to the intense outburst of impulses, results in the development of epilepsy. Epilepsy is typified by recurrent, unprovoked seizures as a result excessive, hypersynchronous discharge of neurons occurs in the brain. Nearly 1% of the population throughout the worldwide is suffering from epilepsy and almost 75% begins at childhood. The patients almost one third are resistant to current available antiepileptic drugs. We don’t have the deep knowledge of the pathophysiology of the disease which can prove useful in further research for drugs with new mechanisms of action for diseases. This paper covers the role various neurotransmitters and neuropeptides in the pathophysiology of epilepsy. Our objective is to introduce the scientists with that aspect of the disease which may prove useful for further development of new drugs of epilepsy to overcome the resistance shown by the patientsorithm.
14 October 2025 in Epilepsy and paroxysmal conditions
Bioelectronic medicine is a field of study that is constantly evolving as a result of recent advancements and improvements in bioelectronic technology, which have led to novel approaches and perspectives in disease diagnosis and therapy, particularly in the inflammatory reflex immuno-regulatory functioning and, vagus nerve stimulation (VNS). The vagus nerve, an elongated nerve in the autonomic nervous system, controls a number of physiological processes in humans, including blood pressure, breathing rate, vasomotor activity, and certain reflex movements. Recent bioelectronic research has led to clinical tests using VNS for inflammatory diseases and other conditions. By sending steady, gentle electric impulses through the vagus nerve to the brain, bioelectronic devices can activate the vagus nerve. The integration of artificial intelligence (AI) with bioelectronic medicine is transforming drug development processes. AI technology can accelerate or even eliminate many time-consuming tasks, allowing healthcare professionals to use their time more efficiently and ultimately improving healthcare outcomes. This review discusses the vagus nerve’s roles in inflammation, stimulation, and regulation in animal models, as well as its therapeutic potential in treating human inflammation. Additionally, it examines how AI-powered bioelectronic drugs are being explored for conditions such as paralysis and immune disorders, and addresses the challenges of delivering large molecules using these drugs. The article emphasizes current trends, advancements, and the promising future applications of combining AI with bioelectronic medicine.
Schizophrenia is detected as psychological disturbances linked to several abnormalities through vast provinces of information dispensation in several parts of the brain and cognition. Current treatment of this disease is mostly related to dopamine receptor (mainly D2 and D4) blockage. There are certain limitations to these medications, which has diverted the focus of scientists to the involvement of alternative neurochemical targets. Specific psychoactive agents induce positive and cognitive symptoms that resemble those seen in schizophrenia. These agents act by antagonizing N-methyl-d-aspartate (NMDA) receptors. Therefore, this chapter focuses on the role of the glutaminergic system in the pathophysiology of schizophrenia. Glutamate, being the most abundant neurotransmitter, acts as a crossroad for almost all other neurotransmitter systems in one or other way. Dopaminergic deficits are also considered secondary to underlying glutamatergic dysfunction. It has further been postulated that improper functioning of NMDA receptors enhances neurotransmission in the synaptic cleft, leading to excitotoxicity. A further possibility for the enhanced level of glutamate is a defect in the transporter system. Chromosomal and mutational changes may also be studied for glutamate defects, as no systemic study has yet been done in this area. By studying these theories of glutamate neurotransmitter abnormality, in this chapter the authors frame newfangled concepts and treatment methodologies for schizophrenia based on glutaminergic system abnormalities, which may be important in the future for new drug development in schizophrenia.